Cardiology for everyone - News of interest and relevance to general practitioners and non-cardiologist specialities. Part 1

Last updated on: 15.11.2026

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

General information This section has been translated automatically.

General Information About the 2026 ESC Congress in Munich 

With approximately 34,000 participants and speakers from all over the world, the ESC Congress—which took place this year from August 28–31 in Munich—is one of the largest and most internationally renowned cardiology conferences.

It covers topics across the entire spectrum of cardiology, cardiovascular medicine, and related fields.

Here, the results of groundbreaking clinical trials and practice-relevant research findings are presented to the international professional community for the first time.

This year’s ESC Congress was the largest ESC Congress to date, and 180 of the study results presented were simultaneously published in renowned journals such as the New England Journal of Medicine, The Lancet, JAMA, and others. 

Of particular importance to all colleagues working in clinical practice: for the first time, three new guidelines and a new internationally recognized definition of myocardial infarction (MI) were presented to the professional community.

These will redefine the standard of medical care in the future, shape clinical practice, and be directly applied in the treatment of patients with cardiovascular disease (CVD).

Important innovations in the field of cardiology—for example, in the areas of interventional cardiology and digital medicine—were also part of the program, and their relevance and future impact on clinical practice were critically discussed and evaluated in the international forum
This year featured several groundbreaking, interesting innovations and
The spotlight topic was the ubiquitous and highly topical future theme of artificial intelligence (AI).

In his opening address, ESC President Prof. Dr. Thomas F. Lüscher highlighted the far-reaching, almost limitless possibilities and the relevance of digitalization and AI for the future of cardiology, as well as their significance for the care of patients with cardiovascular diseases, and placed them in a critical context.

In the future, AI could serve as a “co-pilot”—an important tool in scientific research and a support in clinical medical practice. It has the potential to profoundly transform and improve medical care in many areas, particularly in times of scarce resources. However, it is all the more important that its application be adequately evaluated, evidence-based, and tailored to the specific individual case of each patient. 

AI cannot and will not replace the physician, but it can support decision-making in many areas of medical practice—
. Ultimately, however, responsibility remains with the physician. 

More than ever before, critical judgment and a sense of ethical responsibility—alongside traditional knowledge and logic—are required in medical practice to prevent the blanket, ill-considered, and uncritical use of AI and to avoid “deskilling” in the medical profession, and to prevent physicians from becoming mere assistants to AI, emphasized Prof. Lüscher, who handed over his position to his successor, Prof. Cecilia M. Linde (Karolinska Institute, Sweden), at the end of the congress.

This year’s conference was remarkable in many respects and was certainly of interest not only to cardiologists. This report aims to spark interest in why that is:

Cardiovascular diseases are already of enormous importance in all areas of medicine due to their high mortality and morbidity rates. Added to this are cardiovascular risk factors that share common causes for several chronic diseases manifesting in different organ systems (high blood pressure, diabetes, lipid metabolism disorders, chronic inflammation, obesity).
Against this backdrop, a paradigm shift has recently become increasingly apparent in cardiology, one that places greater emphasis on cardiometabolic and cardiorenal relationships and has been significantly driven by the introduction of SGLT2 inhibitors (SGLT2i) in the treatment of heart failure. 

SGLT2i are now a common, cause-oriented foundational treatment for diabetes, CKD, and all forms of heart failure (HF)—conditions that frequently occur together. For the first time, SGLT2i allow for the uniform treatment of all forms of HF regardless of ejection fraction (EF) and also offer, for the first time, a treatment option for the increasingly common HF with preserved ejection fraction (HFpEF), which is overwhelmingly associated with obesity and metabolic comorbidities.
Furthermore, due to the mechanism of action of SGLT2i, the increased risk of chronic kidney disease (CKD) in patients with cardiovascular disease (CVD), thereby avoiding the interactions between the heart and kidneys—which have so often limited treatment options and significantly worsened the prognosis of patients with CVD—that have been so prevalent until now.

This provides a unique opportunity to significantly improve care for all patients through a transdisciplinary approach and close collaboration. Together with the growing importance of prevention and the treatment of risk factors, this opens up the possibility of early intervention and the prevention of progression to severe, irreversible forms of the disease. The new guidelines clearly reflect these changes.

First, we will present some of these important changes, followed by a small selection of key studies whose findings are interesting and may be relevant beyond the day-to-day practice of cardiology (see Part 2). Finally, we will provide some preliminary insights into several future trends that could fundamentally change everyday clinical practice in the future. The most important of these at present is AI, which was the main focus of this conference.

Important Advances in Treatment in General:

  • Diagnosis and treatment of CVD as early as possible to prevent progression
  • Prevention and rehabilitation as key components of treatment
  • A transdisciplinary approach that takes into account pathophysiological mechanisms and interactions across organ systems and incorporates them into management.

 

New ESC Guidelines for the Treatment of Heart Failure 2026:
The new guidelines on heart failure represent a fundamentally new concept in the management of heart failure and reflect the paradigm shift toward a treatment approach that is more strongly oriented toward pathophysiological causes and transdisciplinary integration, with early diagnosis and therapy to prevent progression, and risk assessment and early-stage intervention are already incorporated into management.

Key changes in this new guideline:

- In the future, only two forms of HF will be distinguished:

HFrEF (≤50%)and HFpEF(≥50%) (HFmrEF 40–49% has been removed).

- The term “acute HF ” is replaced by “decompensated HF.”

New HF staging from A to D: This classification already encompasses the presence of risk factors and early signs of HF (A) through to advanced-stage HF (D) and is in accordance with the guidelines of the AHA, AAC, HFSS, in light of the increasingly important role of prevention, early detection, and treatment in preventing rapid progression.

- Stage A: Risk of HF present; no structural changes
- Stage B: Early stage (pre-HF) with structural changes or abnormal biomarkers but no symptoms.
- Stage C: Manifest symptomatic HF (HfrEF ≤ 50% and HfpEF ≥ 50%)
- Stage D: Advanced HF with repeated hospitalizations

Important: The treatment recommendations have been updated. The four medications previously recommended in the guidelines (“fantastic four”) will now serve as the foundational therapy for all HF patients.

This means:
- For all patients with HFrEF ≤50%, the combined quadruple therapy consisting ofan SGLT2i, an MRA,an ACEi/ARNI or ARB, and a beta-blocker will, in principle, be the uniform standard of care as foundational therapy going forward.
- For all patients with HFpEF ≥50%, the baseline therapy consistsof an SGLT2iandan nsMRA (finerenone) (especially in patients at risk for CKD)
This regimen is supplemented only when indicated by additional guideline-based pharmacological or interventional therapy aimed at reducing morbidity and improving quality of life (the need for such intervention is determined on a case-by-case basis).
Loop diuretics are an additional pharmacological therapy and are indicated only in the presence of signs of congestion.
New: the option of additional pharmacological therapy for weight loss with semaglutide and tirzepatide for patients with HFpEF and obesity (BMI ≥ 30) (Class IIa recommendation).
(Author’s note: Obesity is a key causal factor for HFpEF, and visceral fat is a negative prognostic factor. Whether this guideline recommendation will actually lead to improved care for the primarily affected patient groups likely depends to a large extent on whether statutory health insurance will cover the costs of drug therapy in the future).

Noninvasive imaging will play a greater role in cardiac diagnostics in the future, contributing to improved cause-orientedtreatment

(Cardiomyopathies: echocardiography/MRI; MI and coronary artery disease: echocardiography, MRI, CCTA alongside invasive catheter-based imaging diagnostics; individual risk stratification for prevention: echocardiography/Doppler as needed and, if necessary, additional CCTA).

Targeted, specific diagnosis and treatment of the causes of HF should be initiated as early as possible upon suspicion (e.g., amyloidosis, since early use of new medications—stabilizers and silencers—is crucial to prevent amyloid deposits and HF progression!)

Early referral of patients with advanced HF (advanced HFrEF) to specialized HF centers (simplified diagnostic criteria for advanced HF can be found in the guidelines).

All patients with HF should receive rehabilitation and exercise programs; telemonitoring is recommended when necessary
, along with additional, separate patient recommendations for self-care,  lifestyle recommendations, tips, and health literacy training to support self-management and improved outpatient self-care, reduce morbidity and hospitalization rates, and enhance quality of life (see also the first ESC Guidelines on Cardiac Rehabilitation 2026).

For details, see: Køber L et al. 2026 ESC Guidelines for the Management of Heart Failure. European Heart Journal (2026) 00, 1–112 https://doi.org/10.1083/eurheartj/ehag100


First joint ESC guideline in collaboration with the ERA (European RenalAssociation) on the management of CVD and CKD 2026.
The goal is the early detection and prevention of CKD progression in patients with CVD using a joint, tailored, and integrated transdisciplinary treatment approach for both conditions through the STAMP on CKD concept.

In simple terms,STAMP stands for:
Screening: uACR and eGFR measurement in all patients with CVD

T​​​​​​​​​​​​​riage and Staging: Classification and staging of CKD in CVD based on test results and the KDIGO heatmap (color coding) (included in the guidelines).

Address CKD Risk: Early risk factor management and treatment. Avoid nephrotoxic medications; early pharmacological treatment of CKD progression/CVD risk with Class I drugs, particularly SGLT2i, statins, etc.; Target RR ≤120–129 SAP with ACEi and ARB; Type 2 DM + albuminuria: SGLT2i, if necessary GLP-1RA (semaglutide), and nsMRA (finerenone); Do not discontinue renoprotective medication in the event of a minor decline in eGFR! (see treatment algorithms in the guidelines); Risk classification: using SCORE2/SCORE2-OP plus KFRE (Kidney Failure Risk Equation) as a CKD add-on)

Modify: Adapt standard treatment for CVD (e.g., HF, ASCVD, arrhythmias) to coexisting CKD to make treatment safer. (For specific recommendations regarding the particularities of pharmacotherapy and interventions, see the guidelines).

Plan health services: Improve collaboration and communication between cardiology, nephrology, and patients.
(Among other things, the guideline provides specific recommendations on tailored pharmacotherapy for CVD and CKD with and without DM, atherosclerosis, and arrhythmias, as well as on specific dosing considerations for CKD, and recommendations for contrast-enhanced imaging in CKD).
It also addresses the association between CKD and cerebrovascular diseases
including the prevention of common risk factors (e.g., anticoagulation for AF, acute stroke treatment, and secondary prevention in patients with CVD and CKD).

For details, see: Damman K et al. 2026 ESC Guidelines for the Management of Cardiovascular Diseaseand Chronic Kidney Disease, in collaboration with the European Renal Association (ERA). European Heart Journal (2026) 00, 1–102 https://doi.org/10.1093/eurheartj/ehag098

 

First ESC Guideline onCardiac Rehabilitation 2026:
The first comprehensive and standalone guideline on cardiac rehabilitation aims to summarize all aspects of this topic in the form of recommendations, while giving equal consideration to shared decision-making and, in particular, the individual situation and perspective of patients.

Rehabilitation is understood as a multimodal, patient-centered, collaborative process that
is intended to significantly improve the outcomes and prognosis of patients with chronic diseases and, in line with WHO objectives, should therefore play a key role in healthcare—including in the treatment of cardiovascular diseases (CVD).
In addition to reducing mortality and morbidity, the primary goal is to improvequality oflife, as well as physical and mental functioning in all areas of life.

The measures are intended to be integrated across all stages of treatment:
Phase 0: Pre-rehabilitation (beginning even before treatment starts, e.g., before complex procedures or surgery);
Phase I: During acute treatment (concurrent);
Phase II: during the post-acute phase (structured secondary prevention, either inpatient at a rehabilitation center
or at home)
Phase III: with long-term support and health promotion (taking into account
preventive measures and as part of chronic disease management).

Rehabilitation measures should be initiated as early as possible, taking the patient’s current health status into account.

The recommendations cover the entire spectrum of cardiovascular diseases and coexisting comorbidities (multidisciplinary evaluation and treatment).
Included are recommendations on: optimization of pharmacotherapy, management of comorbidities; measures to promote work capacity and return to work; counseling, exercise therapy and fitness training, nutritional counseling and management, smoking cessation, psychosocial counseling and sexual counseling, and counseling on risk factors and environmental influences—with the goal of promoting and strengthening sustainable self-management, behavioral change, and health literacy.

Interventions can be conducted on an inpatient or outpatient basis, at home, or in a hybrid format, and ideally should incorporate digital monitoring and utilize AI and telemedicine. (e.g., continuous digital monitoring to improve adherence and ensure training safety)

For details, see: Bäck M et al. 2026 ESC Guidelines on Cardiac Rehabilitation. European Heart Journal (2026) 00, 1–99. https://doi.org/10.1083/eurheartj/ehag099.


5.Newinternationallyaccepted definition of myocardial infarction (MI) (joint consensus statement by the ESC, AAC, and WHF (World Heart Federation)) (UDMI5).

This replaces the previously valid definition and now distinguishes between three clinical forms of myocardial infarction: primary, secondary, and intervention-related.

This is intended to better reflect the underlying pathophysiological mechanisms and to incorporate clinical evaluation and objective diagnostic criteria that are essential for treatment and
prognosis. 

Primary MI: primary acute coronary pathology: atherothrombosis, spontaneous coronary artery
dissection (SCAD), coronary embolism, vasospasm, restenosis, stent thrombosis, or bypass occlusion ≥30 days after intervention (this is considered a new event, not intervention-related).

Secondary MI: acute myocardial injury or myocardial ischemia caused by an imbalance
between oxygen supply and oxygen consumption due to another acute condition; e.g., anemia, hypoxia, hypotension, hypertension, tachycardia.

Intervention-related MI: acute myocardial injury as a complication resulting from a percutaneous or surgical procedure within 30 days of interventional treatment (percutaneous or surgical).

The diagnosis is made based on clinical signs, biomarkers, ECG, and coronary or cardiac imaging (a single negative criterion cannot rule out the diagnosis!)
(In areas with limited medical resources (e.g., no cardiac imaging): the presumptive diagnosis is made based on clinical signs and ECG, and biomarkers if available)
.

Biomarker diagnostics: The reference ranges for troponin are adjusted by sex according to the 99th percentile to capture even the smaller changes in troponin levels in women and to enable improved early diagnosis of MI in women.

Imaging: In addition to invasive imaging (coronary angiography), noninvasive imaging—particularly CMRT and CCTA—will play a broader role in the diagnosis of MI (e.g., especially in the diagnosis of secondary MI).

For details,see: Mills NL et al.Fifth Universal Definition of Myocardial Infarction2026. European Heart Journal (2026) 00, 1–48. https://doi.org/10.1083/eurheartj/ehag101

 

Literature This section has been translated automatically.

  1. Bäck M et al. 2026 ESC Guidelines on Cardiac Rehabilitation. European Heart Journal (2026) 00, 1–99. https://doi.org/10.1083/eurheartj/ehag099.
  2. Damman K et al. 2026 ESC Guidelines for the Management of Cardiovascular Disease and Chronic Kidney Disease, in collaboration with the European Renal Association (ERA). European Heart Journal (2026) 00, 1–102 https://doi.org/10.1093/eurheartj/ehag098
  3. Køber L et al. 2026 ESC Guidelines for the Management of Heart Failure. European Heart Journal (2026) 00, 1–112 https://doi.org/10.1083/eurheartj/ehag100
  4. Mills NL et al. Fifth Universal Definition of Myocardial Infarction 2026. European Heart Journal (2026) 00, 1–48. https://doi.org/10.1083/eurheartj/ehag101

     

 

Last updated on: 15.11.2026